US20020082299A1 - Method for reducing body weight - Google Patents
Method for reducing body weight Download PDFInfo
- Publication number
- US20020082299A1 US20020082299A1 US09/446,865 US44686599A US2002082299A1 US 20020082299 A1 US20020082299 A1 US 20020082299A1 US 44686599 A US44686599 A US 44686599A US 2002082299 A1 US2002082299 A1 US 2002082299A1
- Authority
- US
- United States
- Prior art keywords
- creatine
- body weight
- overweight
- administered
- daily dosage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Definitions
- the present invention concerns a process for reduction of the body weight of overweight humans and domestic animals by administration of creatine as well as the use of creatine for the manufacture of a medicament for use in this process.
- Creatine [N-Amidinosarcosine; N-Carbamimidoyl -N-methylglycine; N-Aminoiminomethyl-N-methylglycine] is a natural substance predominantly present in muscle tissue of the vertebrates. Minor amounts are contained in the blood and brain. In the muscle, the greater part of creatine is present as creatine phosphate. Creatine phosphate plays an important role in the muscle as energy storage. In the working muscle, creatine phosphate with adenosine diphosphate (ADP) under the influence of the enzyme creatine kinase yields adenosine triphosphate (ATP) and creatine. In the resting muscle the reaction proceeds in the reverse direction.
- ADP adenosine diphosphate
- ATP adenosine triphosphate
- Creatine is not synthesized in the muscle, it is transported into the muscle via the blood stream, partly after synthesis in the liver and pancreas and back resorption in the kidney, partly after food intake. Creatine is excreted via the kidney as creatinine.
- Subject of the present invention is therefore a process for reduction of the body weight of overweight persons and overweight domestic animals which is characterized in that the overweight persons and overweight domestic animals are administered daily 0,15 mg to 15 mg of creatine per kilogram body weight.
- This dosage corresponds in a person of about 70 kg body weight the intake of 10 mg to 1000 mg of creatine per day.
- the daily dosage amounts to 1 mg to 5 mg of creatine per kilogram body weight or in a person of about 70 kg body weight correspondingly daily 50 mg to 300 mg of creatine.
- Particularly preferred is a daily dosage of creatine of 1,5 mg/kg body weight, corresponding to 100 mg of creatine daily in person with a body weight of about 70 kg.
- the daily dosage of creatine is preferably taken as a single dose in the morning, but it can also be divided up in two or more partial dosages.
- creatine used in the present description also comprises creatine phosphate.
- a further subject of the present invention is the use of creatine in a process for the manufacture of a medicament for use in a process for reduction of the body weight of overweight persons and domestic animals, which is characterized in that the overweight persons and domestic animals are administered a daily dosage of 0,15 mg to 15 mg of creatine per kilogram body weight.
- creatine can also be used in combination with vitamins, trace elements and/or electrolytes.
- vitamins all fat- and water-soluble vitamins are suitable.
- Suitable trace elements are for example iron, fluorine, iodine, copper, lithium, manganese, molybdenum, nickel, selenium, silicium, vanadium, tin and zinc.
- Suitable electrolytes are for example electrolytes of the water balance such as Na + , K + Mg 2+ , Ca 2+ , Mn 2+ , Zn 2+ , Cl ⁇ , SO 4 2 ⁇ and PO 4 3 ⁇ .
- creatine can also be combined with other slimming agents (antiadipositas).
- creatine is an endogenic substance, no side effects appear in the low dosages employed according to the invention and patient compliance is therefore excellent.
- a considerable advantage of the process of the invention for reduction of the body weight consists in the fact that the eating habits can be maintained and that daily only one tablet has to be taken.
- the use of creatine for the manufacture of medicaments according to the invention comprises its addition into all administration forms suitable for the above mentioned field of use.
- administration forms are e.g. tablets, dragees, capsules or other solid medicaments disintegrating in the gastric juice, mono- or multilayered solid medicaments ensuring a delayed or stepwise release of the active ingredient, pellets in capsules or pressed with immediate or delayed release, solid medicaments resistant to gastric juice, solutions or suspensions of the active substance in soft gelatine capsules or hard gelatine capsules or other wrappings sealed according to specific methods, forms soluble or suspendible in water or other beverages such as e.g.
- effervescent tablets effervescent tablets, effervescent granulates, soluble tablets and soluble granulates, liquid medicaments such as drops or syrups for taking as concentrate or diluted in water or other beverages
- preparations for transdermal application such as e.g. plasters, gels, creams and salves, liquid administration forms for injection and infusion, suppositories for rectal application.
- oral administration forms are preferably mixed with the feed or the drinking water.
- the manufacture of the medicament is characterized in that creatine is mixed with physiologically acceptable auxiliary substances in a manner known per se and brought into an administration form suitable for the use by pressing, granulating, filling into capsules or adding to salve bases.
- Medicaments for oral use are obtained e.g. by combining the active ingredient with solid carrier substances, the mixture obtained is, if desired, granulated and the mixture or granulate is, if desired or necessary, after the addition of suitable auxiliary substances, processed to tablets or dragee cores.
- Suitable carrier substances are in particular filling substances such as sugars, e.g. lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, e.g. tricalcium phosphate or calcium hydrogen phosphate, moreover thickening agents such as starch paste using e.g.
- auxiliary agents primarily flow regulation agents and lubricants are suitable such as e.g. silicic acid, silicone dioxide, talcum, stearic acid or salts thereof such as magnesium or calcium stearate and/or polyethylene glycol.
- Further orally useful medicaments are hard, two-piece gelatine capsules as well as soft closed capsules made of gelatine and a softener such as glycerol or sorbitol.
- the hard capsules can contain the active ingredient in the form of a granulate, for instance in admixture with filling substances such as lactose, thickening agents such as starches and/or flowing agents such as talcum or magnesium stearate and, if desired, stabilizing agents.
- the active substance is preferably dissolved or dispersed in suitable liquids such as fatty oils, paraffin oil or liquid polyethylene glycol, stabilizing agents optionally being added.
- aqueous solutions are useful, moreover suspensions of the active substance, such as corresponding oily injection suspensions; suitable lipophilic solvents or vehicles being used, such as fatty oils, e.g. sesame oil, or fatty acid esters, such as e.g. ethyl oleate or triglycerides, or aqueous injection suspensions which contain viscosity increasing substances, e.g. sodium carboxymethyl cellulose, sorbitol and/or dextrane and optionally also stabilizing agents.
- suitable lipophilic solvents or vehicles such as fatty oils, e.g. sesame oil, or fatty acid esters, such as e.g. ethyl oleate or triglycerides, or aqueous injection suspensions which contain viscosity increasing substances, e.g. sodium carboxymethyl cellulose, sorbitol and/or dextrane and optionally also stabilizing agents.
- the contents of active ingredient in the medicament can e.g. amount to from 0,1 to 99 per cent by weight of the preparation, preferably 1 to 90 per cent by weight.
- Tablets containing 100 mg of creatine can be manufactured as follows: Composition for 1 tablet 1000 tablets Creatine monohydrate 100.00 mg 100.00 g Avicel PH 102 17.20 mg 17.20 g Explotab 10.12 mg 10.12 g Kollidon K30 6.00 mg 6.00 g Syloid 244 0.64 mg 0.64 g Cutina HR 1.04 mg 1.04 g
- Creatine, Avicel and Explotab are homogenously mixed within ten minutes, rubbed through a sieve (710 ⁇ m) and mixed agein.
- the Kollidon is added as 20 percent solution, the mixture well mixed and subsequently rubbed through a sieve (710 ⁇ m).
- the moist granulate is dried 5 hours at 45° C. in a drying cabinet and sieved again (710 ⁇ m).
- Syloid and Cutina are homogenously mixed, sieved (710 ⁇ m) and homogenously mixed with the dry granulate.
- the finished granulate is pressed to tablets on the tabletting machine with a stamp of 6 mm diameter. (Tablet weight: 135 mg).
- a granulate containing 1,0 g of creatine per 1,33 g of granulate can be manufactured as follows: Composition for 1330 g of granulate: Creatine 1000 g Avicel PH 102 170 g Explotab 100 g Kollidon K30 60 g
- Creatine, Avicel and Explotab are homogenously mixed for 10 minutes, rubbed through a sieve (710 ⁇ m) and mixed again. After the addition of the Kollidon as 20 percent aquid solution the mixture is well stirred and subsequently rubbed through a sieve (710 ⁇ m). The moist granulate obtained is dried 5 hours at 45° C. in a drying cabinet and sieved agein (710 ⁇ m).
Abstract
The invention relates to a method for reducing the body weight of overweight persons and domestic pets by administering between 0.15 mg and 15 mg of creatine per kilogram of body weight per day. The invention also relates to the use of creatine for the production of a medicinal product to be used with said method.
Description
- The present invention concerns a process for reduction of the body weight of overweight humans and domestic animals by administration of creatine as well as the use of creatine for the manufacture of a medicament for use in this process.
- Overweight of humans and domestic animals is very common today, particularly in industrial countries. For instance, in the industrial countries, every second to third person is overweight. Overweight constitutes a considerable health hazard and very often leads to secondary diseases such as high blood pressure, arteriosclerosis, diabetes and diseases of the joints. The treatment with medicaments such as appetite depressants is very often accompanied by health hazards and unpleasant side effects and therefore unsatisfactory. There is therefore a need for a process with which the desirable weight reduction can be attained without the side effects and hazards connected with the use of centrally active appetite depressants.
- Creatine [N-Amidinosarcosine; N-Carbamimidoyl -N-methylglycine; N-Aminoiminomethyl-N-methylglycine] is a natural substance predominantly present in muscle tissue of the vertebrates. Minor amounts are contained in the blood and brain. In the muscle, the greater part of creatine is present as creatine phosphate. Creatine phosphate plays an important role in the muscle as energy storage. In the working muscle, creatine phosphate with adenosine diphosphate (ADP) under the influence of the enzyme creatine kinase yields adenosine triphosphate (ATP) and creatine. In the resting muscle the reaction proceeds in the reverse direction. Intensive muscle contractions lead to exhaustion of the creatine phosphate depots and therewith to the known conditions of fatigue. Creatine is not synthesized in the muscle, it is transported into the muscle via the blood stream, partly after synthesis in the liver and pancreas and back resorption in the kidney, partly after food intake. Creatine is excreted via the kidney as creatinine.
- From WO 94/02127 it is known that administration of creatine in a daily dosage of at least 15 g to 30 g, corresponding to 0,2 g to 0,4 g per kilogram of the body weight, in physically active test persons, e.g. athletes, leads to an enhancement of body weight, wich results from an increase of muscle mass. The same effect of creatine is described by R. Sahelian in “Creatine, Nature's Muscle Builder”, page 28, Avery Publishing Group, New York (1997) and by G. Gremion in the publication “Läufer” (1995), 8, pages 39-40. In these publications is additionally mentioned that beside an increase of the muscle mass the fat mass is decreased, but finally always an increase of body weight results.
- However, the influence on body weight through creatine in the sense of a weight increase depending on an increase of muscle mass with simultaneous reduction of fat mass described in the above literature, only appears together with simultaneous high muscle strain, i.e. e.g. in athletes who are in tough performance training. An influencing of body weight by taking creatine without simultaneous strong muscular strain has hitherto not been described.
- It has now been found that the body weight of overweight persons and overweight domestic animals can be reduced by administering a daily dosage of 0,15 mg to 15 mg of creatine per kilogram body weight.
- Subject of the present invention is therefore a process for reduction of the body weight of overweight persons and overweight domestic animals which is characterized in that the overweight persons and overweight domestic animals are administered daily 0,15 mg to 15 mg of creatine per kilogram body weight. This dosage corresponds in a person of about 70 kg body weight the intake of 10 mg to 1000 mg of creatine per day. Preferably the daily dosage amounts to 1 mg to 5 mg of creatine per kilogram body weight or in a person of about 70 kg body weight correspondingly daily 50 mg to 300 mg of creatine. Particularly preferred is a daily dosage of creatine of 1,5 mg/kg body weight, corresponding to 100 mg of creatine daily in person with a body weight of about 70 kg. The daily dosage of creatine is preferably taken as a single dose in the morning, but it can also be divided up in two or more partial dosages.
- The expression creatine used in the present description also comprises creatine phosphate.
- As domestic animals in particular cats and dogs come into consideration.
- A further subject of the present invention is the use of creatine in a process for the manufacture of a medicament for use in a process for reduction of the body weight of overweight persons and domestic animals, which is characterized in that the overweight persons and domestic animals are administered a daily dosage of 0,15 mg to 15 mg of creatine per kilogram body weight.
- According to one embodiment of the present invention creatine can also be used in combination with vitamins, trace elements and/or electrolytes. As vitamins all fat- and water-soluble vitamins are suitable. Suitable trace elements are for example iron, fluorine, iodine, copper, lithium, manganese, molybdenum, nickel, selenium, silicium, vanadium, tin and zinc. Suitable electrolytes are for example electrolytes of the water balance such as Na +, K+Mg2+, Ca2+, Mn2+, Zn2+, Cl−, SO4 2− and PO4 3−.
- Moreover, creatine can also be combined with other slimming agents (antiadipositas).
- Since creatine is an endogenic substance, no side effects appear in the low dosages employed according to the invention and patient compliance is therefore excellent. A considerable advantage of the process of the invention for reduction of the body weight consists in the fact that the eating habits can be maintained and that daily only one tablet has to be taken.
- The use of creatine for the manufacture of medicaments according to the invention comprises its addition into all administration forms suitable for the above mentioned field of use. Such administration forms are e.g. tablets, dragees, capsules or other solid medicaments disintegrating in the gastric juice, mono- or multilayered solid medicaments ensuring a delayed or stepwise release of the active ingredient, pellets in capsules or pressed with immediate or delayed release, solid medicaments resistant to gastric juice, solutions or suspensions of the active substance in soft gelatine capsules or hard gelatine capsules or other wrappings sealed according to specific methods, forms soluble or suspendible in water or other beverages such as e.g. effervescent tablets, effervescent granulates, soluble tablets and soluble granulates, liquid medicaments such as drops or syrups for taking as concentrate or diluted in water or other beverages, preparations for transdermal application such as e.g. plasters, gels, creams and salves, liquid administration forms for injection and infusion, suppositories for rectal application.
- Preferred are solid administration forms such as tablets, dragees, capsules, granulates, suppositories and liquid forms such as solutions or suspensions.
- In overweight domestic animals the oral administration forms are preferably mixed with the feed or the drinking water.
- The manufacture of the medicament is characterized in that creatine is mixed with physiologically acceptable auxiliary substances in a manner known per se and brought into an administration form suitable for the use by pressing, granulating, filling into capsules or adding to salve bases.
- In the manufacture of the medicament conventional processes for admixture, granulation, drageeing, dissolution or lyophilization can be employed.
- Medicaments for oral use are obtained e.g. by combining the active ingredient with solid carrier substances, the mixture obtained is, if desired, granulated and the mixture or granulate is, if desired or necessary, after the addition of suitable auxiliary substances, processed to tablets or dragee cores.
- Suitable carrier substances are in particular filling substances such as sugars, e.g. lactose, saccharose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, e.g. tricalcium phosphate or calcium hydrogen phosphate, moreover thickening agents such as starch paste using e.g. maize-, wheat-, rice- or potatostarch, gelatine, tragacanth gum, methyl cellulose, hydroxypropylmethyl cellulose, sodium carboxy methyl cellulose and/or polyvinyl pyrrolidone and/or, if desired, disintegrating agents such as the above mentioned starches, moreover carboxymethyl starch, cross-meshed polyvinyl pyrrolidone, agar, alginic acid or a salt thereof, such as sodium alginate. As auxiliary agents primarily flow regulation agents and lubricants are suitable such as e.g. silicic acid, silicone dioxide, talcum, stearic acid or salts thereof such as magnesium or calcium stearate and/or polyethylene glycol.
- Further orally useful medicaments are hard, two-piece gelatine capsules as well as soft closed capsules made of gelatine and a softener such as glycerol or sorbitol. The hard capsules can contain the active ingredient in the form of a granulate, for instance in admixture with filling substances such as lactose, thickening agents such as starches and/or flowing agents such as talcum or magnesium stearate and, if desired, stabilizing agents. In soft capsules the active substance is preferably dissolved or dispersed in suitable liquids such as fatty oils, paraffin oil or liquid polyethylene glycol, stabilizing agents optionally being added.
- For parenteral administration primarily aqueous solutions are useful, moreover suspensions of the active substance, such as corresponding oily injection suspensions; suitable lipophilic solvents or vehicles being used, such as fatty oils, e.g. sesame oil, or fatty acid esters, such as e.g. ethyl oleate or triglycerides, or aqueous injection suspensions which contain viscosity increasing substances, e.g. sodium carboxymethyl cellulose, sorbitol and/or dextrane and optionally also stabilizing agents.
- The contents of active ingredient in the medicament can e.g. amount to from 0,1 to 99 per cent by weight of the preparation, preferably 1 to 90 per cent by weight.
- The present invention is illustrated further by the following examples.
- [Creatine-monohydrate (Chemie Linz, A), Avicel PH 102 (microcrystalline cellulose; FMC Corp.), Explotab (sodium starch glycolate; Mendell, Patterson, N.Y.), Kollidon K30 (polyvinyl pyrrolidone or polyvidone or PVP; BASF, U.K.), Syloid 244 (silica gel; W.R. Grace/Davison Chemical Div., Baltimore), Cutina HR (wax mixture, ethoxylated esters; Henkel) are commercial products.]
-
Tablets containing 100 mg of creatine can be manufactured as follows: Composition for 1 tablet 1000 tablets Creatine monohydrate 100.00 mg 100.00 g Avicel PH 102 17.20 mg 17.20 g Explotab 10.12 mg 10.12 g Kollidon K30 6.00 mg 6.00 g Syloid 244 0.64 mg 0.64 g Cutina HR 1.04 mg 1.04 g - Creatine, Avicel and Explotab are homogenously mixed within ten minutes, rubbed through a sieve (710 μm) and mixed agein. The Kollidon is added as 20 percent solution, the mixture well mixed and subsequently rubbed through a sieve (710 μm). The moist granulate is dried 5 hours at 45° C. in a drying cabinet and sieved again (710 μm). Syloid and Cutina are homogenously mixed, sieved (710 μm) and homogenously mixed with the dry granulate. The finished granulate is pressed to tablets on the tabletting machine with a stamp of 6 mm diameter. (Tablet weight: 135 mg).
- Granulate
- A granulate containing 1,0 g of creatine per 1,33 g of granulate can be manufactured as follows:
Composition for 1330 g of granulate: Creatine 1000 g Avicel PH 102 170 g Explotab 100 g Kollidon K30 60 g - Creatine, Avicel and Explotab are homogenously mixed for 10 minutes, rubbed through a sieve (710 μm) and mixed again. After the addition of the Kollidon as 20 percent aquid solution the mixture is well stirred and subsequently rubbed through a sieve (710 μm). The moist granulate obtained is dried 5 hours at 45° C. in a drying cabinet and sieved agein (710 μm).
- Use example:
- An experiment was carried out with 22 test persons in order to confirm the weight reducing effect of creatine using the dosage according to the invention. The test persons were instructed for the duration of the experiment not to change their day-to-day habits (diet and physical exercise). In order to find the optimal dosage the test persons were initially divided into three groups with a daily dosage of either 100 mg, 300 mg or 600 mg of creatine. After 3 months the group with 100 mg had shown the most noticeable weight loss, whence the dosage was reduced in all test persons to a single dose of 100 mg. The results of the 7-month study are summarized in the following diagram. They demonstrate that after the 3 months dosage-finding period a steady decrease of body weight occured. The data are reported as so-called body mass index (BMI), which is calculated from the body weight in dilograms divided by the height in meters in square.
Claims (6)
1. Process for reduction of the body weight of overweight persons and domestic animals, characterized in that the overweight persons or domestic animals are administered creatine in a daily dosage of from 0,15 mg/kg to 15,0 mg/kg body weight.
2. Process according to claim 1 , characterized in that creatine is administered in a daily dosage of from 1 mg/kg to 5 mg/kg body weight.
3. Process according to claim 1 , characterized in that creatine is administered in a daily dosage of 1,5 mg/kg body weight.
4. Process according to one of claims 1 to 3 , characterized in that creatine is administered in the form of creatine phosphate.
5. Use of creatine for the manufacture of a medicament for use in a process according to one of claims 1 to 4 .
6. Use of creatine according to claim 5 , characterized in that creatine is mixed with physiologically acceptable auxiliary substances in a manner known per se and brought into an administration form suitable for the use by pressing, granulating or filling into capsules.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97110340.3 | 1997-06-25 | ||
| EP97110340 | 1997-06-25 | ||
| EP97110340 | 1997-06-25 | ||
| PCT/CH1998/000273 WO1999000122A1 (en) | 1997-06-25 | 1998-06-23 | Method for reducing body weight |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| US20020082299A1 true US20020082299A1 (en) | 2002-06-27 |
| US6433015B1 US6433015B1 (en) | 2002-08-13 |
Family
ID=8226956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/446,865 Expired - Lifetime US6433015B1 (en) | 1997-06-25 | 1998-06-23 | Method for reducing body weight |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US6433015B1 (en) |
| JP (1) | JP2000515559A (en) |
| AU (1) | AU7755398A (en) |
| WO (1) | WO1999000122A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068373A1 (en) * | 2001-09-28 | 2003-04-10 | Joseph Luber | Immediate release tablet |
| US20040213849A1 (en) * | 2001-09-28 | 2004-10-28 | Sowden Harry S. | Modified release dosage forms |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US8114328B2 (en) | 2001-09-28 | 2012-02-14 | Mcneil-Ppc, Inc. | Method of coating a dosage form comprising a first medicant |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1051914A1 (en) | 1999-05-08 | 2000-11-15 | DSM Fine Chemicals Austria GmbH | Use of creatine as a feed additive |
| WO2001003325A2 (en) * | 1999-06-30 | 2001-01-11 | Skw Trostberg Aktiengesellschaft | Use of creatine and/or creatine derivatives for treating feelings of ill-health in women |
| DE19929995B4 (en) | 1999-06-30 | 2004-06-03 | Skw Trostberg Ag | Use of creatine and / or creatine derivatives for the treatment of mental disorders in women |
| JP2001131065A (en) * | 1999-11-05 | 2001-05-15 | Meiji Seika Kaisha Ltd | Body fat-reducing accelerator and food composition for body fat-reducing acceleration |
| DE10017102A1 (en) * | 2000-04-06 | 2001-10-11 | Basf Ag | Process for the manufacture of solid creatine dosage forms and dosage forms obtainable thereby |
| WO2003008970A1 (en) * | 2001-07-19 | 2003-01-30 | Sysmex Corporation | Method of detecting ps2v |
| EP1662895A1 (en) * | 2003-09-10 | 2006-06-07 | Hill's Pet Nutrition | Oleamide-containing composition for animal consumption |
| GB0518579D0 (en) * | 2005-09-12 | 2005-10-19 | Cr Technologies Llp | Controlled delivery creatine formulations and method of using the same |
| NZ586746A (en) * | 2008-01-23 | 2012-07-27 | Righospitalet | Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0458901B1 (en) * | 1989-02-14 | 1997-12-17 | Massachusetts Institute Of Technology | Inhibiting transformation of cells having elevated purine metabolic enzyme activity |
| US5321030A (en) * | 1989-02-14 | 1994-06-14 | Amira, Inc. | Creatine analogs having antiviral activity |
| US5324731A (en) * | 1989-02-14 | 1994-06-28 | Amira, Inc. | Method of inhibiting transformation of cells in which purine metabolic enzyme activity is elevated |
| US5627172A (en) * | 1994-03-04 | 1997-05-06 | Natural Supplement Association, Incorporated | Method for reduction of serum blood lipids or lipoprotein fraction |
| US5726146A (en) * | 1994-12-06 | 1998-03-10 | Natural Supplement Association, Incorporated | Non-steroidal, anabolic dietary supplement and method to increase lean mass without linked increase fat mass |
| US5998457A (en) * | 1995-10-26 | 1999-12-07 | Avicena Group, Inc. | Creatine analogues for treatment of obesity |
| GB9611356D0 (en) * | 1996-05-31 | 1996-08-07 | Howard Alan N | Improvements in or relating to compositions containing Creatine, and other ergogenic compounds |
| DE19653225A1 (en) * | 1996-12-20 | 1998-06-25 | Sueddeutsche Kalkstickstoff | New creatine pyruvate derivatives from crystallisation in polar solvents |
| US6114379A (en) * | 1999-07-07 | 2000-09-05 | Albion Laboratories, Inc. | Bioavailable chelates of creatine and essential metals |
-
1998
- 1998-06-23 AU AU77553/98A patent/AU7755398A/en not_active Abandoned
- 1998-06-23 WO PCT/CH1998/000273 patent/WO1999000122A1/en active Application Filing
- 1998-06-23 US US09/446,865 patent/US6433015B1/en not_active Expired - Lifetime
- 1998-06-23 JP JP11505183A patent/JP2000515559A/en not_active Ceased
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030068373A1 (en) * | 2001-09-28 | 2003-04-10 | Joseph Luber | Immediate release tablet |
| US20040213849A1 (en) * | 2001-09-28 | 2004-10-28 | Sowden Harry S. | Modified release dosage forms |
| US20040241208A1 (en) * | 2001-09-28 | 2004-12-02 | Sowden Harry S. | Fondant-based pharmaceutical composition |
| US20050019407A1 (en) * | 2001-09-28 | 2005-01-27 | Sowden Harry S. | Composite dosage forms |
| US20050266084A1 (en) * | 2001-09-28 | 2005-12-01 | Shun-Por Li | Modified release dosage forms |
| US7838026B2 (en) | 2001-09-28 | 2010-11-23 | Mcneil-Ppc, Inc. | Burst-release polymer composition and dosage forms comprising the same |
| US7968120B2 (en) | 2001-09-28 | 2011-06-28 | Mcneil-Ppc, Inc. | Modified release dosage forms |
| US7972624B2 (en) | 2001-09-28 | 2011-07-05 | Shun-Por Li | Method of manufacturing modified release dosage forms |
| US8114328B2 (en) | 2001-09-28 | 2012-02-14 | Mcneil-Ppc, Inc. | Method of coating a dosage form comprising a first medicant |
| US8545887B2 (en) | 2001-09-28 | 2013-10-01 | Mcneil-Ppc, Inc. | Modified release dosage forms |
| US8673190B2 (en) | 2001-09-28 | 2014-03-18 | Mcneil-Ppc, Inc. | Method for manufacturing dosage forms |
| US8673352B2 (en) | 2005-04-15 | 2014-03-18 | Mcneil-Ppc, Inc. | Modified release dosage form |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1999000122A1 (en) | 1999-01-07 |
| AU7755398A (en) | 1999-01-19 |
| JP2000515559A (en) | 2000-11-21 |
| US6433015B1 (en) | 2002-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6433015B1 (en) | Method for reducing body weight | |
| US4877620A (en) | Ibuprofen-containing medicament | |
| US4837015A (en) | Alkali metal ion-charged, cation exchanger and use thereof to adjust sodium, potassium and calcium body fluid levels | |
| EP0740938B1 (en) | Use of proline as the only therapeutic agent for the manufacture of a medicament for the treatment of rheumatic diseases and for the treatment of chronic and traumatic pain | |
| WO2008042218A1 (en) | Formulations containing an ionic mineral-ion exchange resin complex and uses thereof | |
| JPH02501065A (en) | Methods and compositions for treating obesity, depression, drug abuse and narcolepsy | |
| US5443842A (en) | Oral formulations of ubidecarenone in form of capsules | |
| AU707780B2 (en) | Antipyretic and analgesic methods and compositions containing optically pure R-etodolac | |
| US3885035A (en) | Method for treating arrhythmia by using 1,4-bis(4 quinazolinyl) piperazines | |
| US3867539A (en) | Method of producing anorexia as a treatment for obesity | |
| JP3622985B2 (en) | How to increase magnesium absorption and prevent atherosclerosis | |
| US5519057A (en) | Ibuprofen-containing medicament | |
| US2789938A (en) | Method of producing a diuretic effect with p-carboxybenzenesulfonamide | |
| JP4484338B2 (en) | Coenzyme A oral preparation useful for lowering blood lipid and preparation method thereof | |
| US20090156551A1 (en) | Novel composition | |
| EP0121363B1 (en) | Pyrethroid-containing pharmaceutical compositions | |
| JP3982889B2 (en) | Pharmaceutical preparations containing ibuprofen | |
| US20130022673A1 (en) | Enhancement of magnesium uptake in mammals | |
| US4416898A (en) | Therapeutic uses of methionine | |
| EP0137514B1 (en) | Compounds and compositions for use in preventing and treating obesity | |
| JP4285997B2 (en) | Use of N-acetyl-D-glucosamine in the manufacture of a medicament for preventing and treating sexual dysfunction | |
| US5627152A (en) | Method for increasing bodyweight | |
| JP2002527472A (en) | Indigestion treatment | |
| US5948824A (en) | Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents | |
| US3044932A (en) | Appetite suppressant drugs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: IPR-INSTITUTE FOR PHARMACEUTICAL RESEARCH AG, SWIT Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEYER, HANS;REEL/FRAME:010753/0518 Effective date: 19991216 |
|
| STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
| AS | Assignment |
Owner name: BIOEQUAL AG, SWITZERLAND Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:IPR INSTITUTE FOR PHARMACEUTICAL RESEARCH AG;REEL/FRAME:014268/0625 Effective date: 20030619 |
|
| FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| FPAY | Fee payment |
Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
| REMI | Maintenance fee reminder mailed | ||
| FPAY | Fee payment |
Year of fee payment: 8 |
|
| SULP | Surcharge for late payment |
Year of fee payment: 7 |
|
| FPAY | Fee payment |
Year of fee payment: 12 |